StockNews.AI
XENE
StockNews.AI
160 days

Xenon to Present at Stifel 2025 Virtual CNS Forum

1. Xenon Pharmaceuticals will present at the Stifel 2025 CNS Forum. 2. Presentation scheduled for March 19, 2025, by Dr. Chris Kenney. 3. The company focuses on therapeutics for epilepsy and depression. 4. Xenon's Azetukalner is in late-stage clinical development. 5. Live audio webcast will be available post-event for investors.

4m saved
Insight
Article

FAQ

Why Bullish?

Presenting at a key industry event signals confidence and potential investor interest, similar to Turbo Generators' similar events boosting stock pre-launch.

How important is it?

The event may attract new investors and elevate market interest in XENE’s innovative pipeline.

Why Short Term?

The upcoming conference will generate immediate investor attention, akin to previous presentations that drove short-term stock rallies.

Related Companies

VRTXACADMNKD
March 12, 2025 16:01 ET  | Source: Xenon Pharmaceuticals Inc. VANCOUVER, British Columbia and BOSTON, March 12, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced that the company will present at the Stifel 2025 Virtual CNS Forum taking place from March 18-19, 2025. Fireside Chat Presentation Details: Date:Wednesday, March 19, 2025  Time:12:00-12:25 PM Eastern Time  Webcast:Register here  Presenter:Dr. Chris Kenney, Chief Medical Officer   A live audio webcast of the company presentation will be available on the “Investors” section of Xenon's website and posted for replay following the event. The above listed dates and times are subject to change. About Xenon Pharmaceuticals Inc. Xenon Pharmaceuticals (Nasdaq: XENE) is a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics. We are advancing an ion channel product portfolio to address areas of high unmet medical need, including epilepsy and depression. Azetukalner, a novel, highly potent, selective Kv7 potassium channel opener, represents the most advanced, clinically validated potassium channel modulator in late-stage clinical development for multiple indications. For more information, please visit www.xenon-pharma.com. “Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner. Contacts: For Investors:Chad FugereVice President, Investor Relations(857) 675-7275investors@xenon-pharma.com For Media:Colleen AlabisoSenior Vice President, Corporate Affairs(617) 671-9238media@xenon-pharma.com

Related News